Xenetic Biosciences, Inc. is a biopharmaceutical enterprise primarily engaged in advancing XCART, a bespoke chimeric antigen receptor T cell (CAR T) platform technology. This innovative system is engineered to specifically target unique tumor neoantigens found in individual patients. The company's broader efforts encompass the creation of various biologic therapeutics and drugs. A significant aspect of their cell-based therapeutic development is focused on addressing B-cell lymphomas by targeting the B-cell receptor present on the surface of malignant tumor cells unique to each patient. Additionally, Xenetic leverages its proprietary PolyXen drug delivery platform through strategic partnerships with other biotechnology and pharmaceutical firms. Noteworthy collaborations include agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. maintains its corporate headquarters in Framingham, Massachusetts.